Trial Profile
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Durvalumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 May 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.